Mercury Laboratories Ltd
Mercury Laboratories Ltd (MERCURYLAB) last reported results for the quarter ended Jun 2026, with sales of ₹15.96 crore and net profit of ₹0.3 crore. The stock last traded at ₹780, a market capitalisation of ₹93.6 crore, on a P/E of 21.3. Over the past 52 weeks the stock has ranged between ₹621 and ₹943. Figures are as of 6 Oct 2026 and are not real time.
Mercury Laboratories Ltd share price and key metrics
- Current price
- ₹780
- Market cap
- ₹93.6 cr
- Stock P/E
- 21.3
- Book value
- ₹484
- ROE
- 9.19%
- ROCE
- 12.1%
- Dividend yield
- 0.45%
- 52w high / low
- 943/621
Metrics as of 6 Oct 2026. Not real time.
Track Mercury Laboratories Ltd
Cruxal reads every Mercury Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Mercury Laboratories Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 2%
- 3 Years
- 0%
- TTM
- -4%
- 10 Years
- 3%
- 5 Years
- -1%
- 3 Years
- -3%
- TTM
- 17%
- 10 Years
- 4%
- 5 Years
- 2%
- 3 Years
- 0%
- 1 Year
- -8%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 9%
- Last Year
- 9%
Mercury Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15.96 cr, down 12.0% from ₹18.14 cr a year earlier. Net profit was ₹0.3 cr, down 69.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 18.19 | 19.57 | 20.66 | 18.14 | 19.01 | 18.35 | 20.44 | 15.96 |
| Expenses | 16.88 | 17.59 | 18.53 | 15.78 | 16.88 | 15.83 | 18.4 | 14.77 |
| Operating profit | 1.31 | 1.98 | 2.13 | 2.36 | 2.13 | 2.52 | 2.04 | 1.19 |
| OPM % | 7.20% | 10.12% | 10.31% | 13.01% | 11.20% | 13.73% | 9.98% | 7.46% |
| Other income | 0.21 | 0.53 | 0.18 | 0.18 | 0.79 | -0.08 | 0.67 | 0.05 |
| Interest | 0.15 | 0.13 | 0.13 | 0.15 | 0.13 | 0.14 | 0.13 | 0.12 |
| Depreciation | 0.71 | 0.74 | 0.73 | 0.84 | 0.86 | 0.87 | 0.84 | 0.73 |
| Profit before tax | 0.66 | 1.64 | 1.45 | 1.55 | 1.93 | 1.43 | 1.74 | 0.39 |
| Tax % | 22.73% | 27.44% | 23.45% | 37.42% | 14.51% | 30.77% | 29.31% | 23.08% |
| Net profit | 0.5 | 1.19 | 1.11 | 0.97 | 1.64 | 1 | 1.23 | 0.3 |
| EPS (₹) | 4.17 | 9.92 | 9.25 | 8.08 | 13.67 | 8.33 | 10.25 | 2.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mercury Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.02 | 51.86 | 55.52 | 57.27 | 68.6 | 57.92 | 75.33 | 75.56 | 75.1 | 75.94 | 73.76 |
| Operating profit | 6.72 | 4.42 | 5.73 | 6.17 | 9.59 | 7 | 8.6 | 9.03 | 7.02 | 9.03 | 7.88 |
| OPM % | 13.99% | 8.52% | 10.32% | 10.77% | 13.98% | 12.09% | 11.42% | 11.95% | 9.35% | 11.89% | 10.68% |
| Net profit | 2.7 | 2.01 | 2.84 | 3.23 | 5.34 | 3.56 | 5.58 | 5.65 | 3.14 | 4.83 | 4.17 |
| EPS (₹) | 22.50 | 16.75 | 23.67 | 26.92 | 44.50 | 29.67 | 46.50 | 47.08 | 26.17 | 40.25 | 34.75 |
TTM is the trailing twelve months to the most recent quarter.
Mercury Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
| Reserves | 23.27 | 25.15 | 27.77 | 30.78 | 35.69 | 39.11 | 44.43 | 49.64 | 52.37 | 56.88 |
| Borrowings | 7.44 | 9.76 | 9.56 | 7.19 | 7.10 | 5.99 | 5.83 | 5.55 | 5.45 | 8.43 |
| Other liabilities | 19.23 | 15.59 | 18.76 | 17.13 | 21.38 | 16.14 | 12.70 | 11.56 | 15.21 | 12.57 |
| Total liabilities | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.95 | 74.23 | 79.08 |
| Fixed assets | 18.39 | 20.78 | 24.39 | 23.66 | 26.36 | 25.82 | 24.26 | 24.03 | 24.64 | 23.88 |
| CWIP | 0.40 | 0.24 | -0.00 | -0.00 | -0.00 | -0.00 | 0.13 | 3.82 | 9.32 | 9.82 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other assets | 32.34 | 30.67 | 32.89 | 32.63 | 39.00 | 36.61 | 39.76 | 40.09 | 40.26 | 45.37 |
| Total assets | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.95 | 74.23 | 79.08 |
As reported by the company. Total assets equal total liabilities by construction.
Mercury Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.92 | 4.97 | 5.22 | 5.49 | 8.21 | 5.19 | 2.45 | 8.23 | 4.86 | 4.24 |
| Cash from investing | -1.50 | -3.68 | -4.99 | -1.14 | -4.62 | -1.89 | -1.06 | -6.27 | -9.04 | -3.17 |
| Cash from financing | -0.25 | 1.07 | -2.54 | -3.33 | -1.24 | -1.23 | -1.01 | -1.04 | -1.85 | 2.91 |
| Net cash flow | 0.17 | 2.36 | -2.31 | 1.02 | 2.36 | 2.07 | 0.38 | 0.91 | -6.03 | 3.99 |
| Free cash flow | 0.42 | 1.29 | 0.23 | 4.35 | 3.59 | 3.30 | 1.39 | 1.96 | -4.18 | 1.07 |
| CFO / operating profit | 45% | 129% | 109% | 109% | 100% | 101% | 41% | 105% | 103% | 61% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Mercury Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.91% | 9.82% | 13.77% | 13.26% | 20.56% | 11.83% | 16.04% | 13.41% | 8.94% | 12.06% |
| Debtor days | 133.25 | 103.60 | 126.82 | 115.61 | 119.93 | 105.49 | 103.55 | 105.55 | 125.10 | 124.25 |
| Inventory days | 137.30 | 119.80 | 93.95 | 78.44 | 60.42 | 104.59 | 82.82 | 75.88 | 92.47 | 89.34 |
| Days payable | 186.56 | 138.65 | 161.71 | 120.01 | 137.94 | 105.98 | 76.58 | 63.30 | 126.07 | 78.42 |
| Cash conversion cycle | 83.99 | 84.75 | 59.05 | 74.04 | 42.41 | 104.10 | 109.79 | 118.13 | 91.50 | 135.16 |
| Working capital days | 102.84 | 90.58 | 88.75 | 88.78 | 75.02 | 79.02 | 87.02 | 91.64 | 106.68 | 130.16 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Mercury Laboratories Ltd shareholding pattern
Promoters held 73.66% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
| Public | 26.36% | 26.34% | 26.34% | 26.34% | 26.34% | 26.35% | 26.34% | 26.34% |
| No. of shareholders | 1,345 | 1,411 | 1,397 | 1,384 | 1,365 | 1,321 | 1,316 | 1,328 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Mercury Laboratories Ltd corporate filings
- Certificate under Reg 74(5) of SEBI (DP) regulations, 2018 for the quarter ended on September 30, 2026 is attachedCompany Updatelow impact
- Regulatory Filing Indicates Cessation of Non-Executive Director Post-AGM, No Immediate Financial ImpactCompany Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has announced the cessation of Non-Executive Director Mr…
Read the full analysis - Corporate Voting Results of Mercury Laboratories Limited for 45th AGM (2026): Majority Approves Financials and Resolutions, with Notable Shareholder Support for Key ItemsAGM/EGMmedium impact
Cruxal's analysis: Mercury Laboratories Limited's 45th AGM held on September 28, 2026, saw high…
Read the full analysis - Mercury Laboratories Limited concludes 45th AGM; declares dividend of INR 3.50 per shareAGM/EGMlow impact
Cruxal's analysis: Mercury Laboratories Limited has successfully concluded its 45th Annual General Meeting…
Read the full analysis - Intimation of closure of trading window for the announcement of unaudited financial statment for the quarter and half year ended on September 30, 2026Insider Trading / SASTlow impact
- Mercury Laboratories Limited announces appointment of Mr. Jaydeepsinh Raj as Manager-HRCompany Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has formally announced the appointment of Mr. Jaydeepsinh…
Read the full analysis - Mercury Laboratories Limited announces 45th Annual General Meeting (AGM) scheduled for September 28, 2026Company Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has issued a formal notice for its 45th Annual General…
Read the full analysis - Mercury Laboratories Ltd releases 45th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Mercury Laboratories Ltd has filed its 45th Annual Report for the financial year ended…
Read the full analysis - Mercury Laboratories Limited Announces 45th AGM, Dividend Declaration, and Related Party Remuneration ApprovalsAGM/EGMlow impact
Cruxal's analysis: Mercury Laboratories Limited has scheduled its 45th Annual General Meeting for September…
Read the full analysis - Mercury Laboratories Limited Announces 45th Annual General Meeting (AGM) for September 28, 2026Company Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has issued an intimation regarding its 45th Annual General…
Read the full analysis - Mercury Laboratories Limited announces leadership transition in Injectable Production departmentCompany Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has announced the resignation of Ms. Seema Salvi, Head of…
Read the full analysis - Mercury Laboratories Limited announces record date for dividend of INR 3.5 per share for FY 2025-26Company Updatelow impact
Cruxal's analysis: Mercury Laboratories Limited has declared a dividend of INR 3.5 per equity share (face…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.